Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Juan Carlos Mesa Gutiérrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, Nùria Planas Domènech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L&amp...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Juan Carlos Mesa Gutiérrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, Nùria Planas Domènech, et al
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e4ad3330c3554ab49b25280bd144d86b
record_format dspace
spelling oai:doaj.org-article:e4ad3330c3554ab49b25280bd144d86b2021-12-02T07:37:29ZIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion1177-54671177-5483https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b2008-09-01T00:00:00Zhttp://www.dovepress.com/intravitreal-bevacizumab-avastin-in-the-treatment-of-macular-edema-sec-a2152https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Juan Carlos Mesa Gutiérrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, Nùria Planas Domènech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, SpainObjective: To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO).Methods: Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV).Results: The median age was 66 years (± 4.16), and the median duration of symptoms was 4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up.Keywords: Bevacizumab, retinal vein occlusion, intravitreal injection, vascular endothelial growth factor Juan Carlos Mesa GutiérrezLuis Arias BarquetJosep Maria Caminal MitjanaSergi Prades AlmoldaNùria Planas Domènechet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 4, Pp 787-791 (2008)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Juan Carlos Mesa Gutiérrez
Luis Arias Barquet
Josep Maria Caminal Mitjana
Sergi Prades Almolda
Nùria Planas Domènech
et al
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
description Juan Carlos Mesa Gutiérrez, Luis Arias Barquet, Josep Maria Caminal Mitjana, Sergi Prades Almolda, Nùria Planas Domènech, Octavi Pujol Goita, Marc Rubio Caso, Jorge Arruga GinebredaDepartment of Ophthalmology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, SpainObjective: To evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO).Methods: Prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV).Results: The median age was 66 years (± 4.16), and the median duration of symptoms was 4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up.Keywords: Bevacizumab, retinal vein occlusion, intravitreal injection, vascular endothelial growth factor
format article
author Juan Carlos Mesa Gutiérrez
Luis Arias Barquet
Josep Maria Caminal Mitjana
Sergi Prades Almolda
Nùria Planas Domènech
et al
author_facet Juan Carlos Mesa Gutiérrez
Luis Arias Barquet
Josep Maria Caminal Mitjana
Sergi Prades Almolda
Nùria Planas Domènech
et al
author_sort Juan Carlos Mesa Gutiérrez
title Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_short Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_fullStr Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full_unstemmed Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_sort intravitreal bevacizumab (avastin) in the treatment of macular edema secondary to retinal vein occlusion
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/e4ad3330c3554ab49b25280bd144d86b
work_keys_str_mv AT juancarlosmesagutiampeacuterrez intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
AT luisariasbarquet intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
AT josepmariacaminalmitjana intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
AT sergipradesalmolda intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
AT nampugraveriaplanasdomampegravenech intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
AT etal intravitrealbevacizumabavastininthetreatmentofmacularedemasecondarytoretinalveinocclusion
_version_ 1718399311825338368